Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 24;5(8):e1203498.
doi: 10.1080/2162402X.2016.1203498. eCollection 2016 Aug.

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors

Marina Bacac  1 , Christian Klein  1 , Pablo Umana  1
Affiliations

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors

Marina Bacac et al. Oncoimmunology. .

Abstract

Carcinoembryonic antigen T cell bispecific antibody (CEA TCB) is a bispecific antibody used to recognize CEA and CD3e via a novel molecular format (2:1) that induces T cell-mediated killing of CEA over-expressing tumors while sparing primary cells with low CEA expression. CEA TCB treatment inhibits tumor growth and generates a highly inflamed tumor microenvironment.

Keywords: Bispecific; T cell.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of selected clinical stage T cell bispecific antibodies: (A) tandem scFv (BiTE) format, (B) asymmetric 1:1 heterodimeric IgG-based TCB, (C) asymmetric 2:1 heterodimeric IgG-based CEA CD3 TCB; (D) Infiltration of CD3+ T cells into poorly infiltrated MKN45 tumors in PBMC-engrafted NOG mice treated with vehicle, CEA CD3 TCB and an untargeted control TCB, modified from with permission from Clinical Cancer Research.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Frankel SR, Baeuerle PA. Targeting t cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17(3):385-92; PMID:23623807; http://dx.doi.org/10.1016/j.cbpa.2013.03.029 - DOI - PubMed
    1. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M et al.. Tumor regression in cancer patients by very low doses of a t cell-engaging antibody. Science 2008; 321(5891):974-7; PMID:18703743; http://dx.doi.org/10.1126/science.1158545 - DOI - PubMed
    1. Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S et al.. Fda approval: Blinatumomab. Clin Cancer Res 2015; 21(18):4035-9; PMID:26374073; http://dx.doi.org/10.1158/1078-0432.CCR-15-0612 - DOI - PubMed
    1. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al.. Anti-cd20/cd3 t cell-dependent bispecific antibody for the treatment of b cell malignancies. Sci Transl Med 2015; 7(287):287ra270; PMID:25972002; http://dx.doi.org/2665927310.1126/scitranslmed.aaa4802 - DOI - PubMed
    1. Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J et al.. A novel, native-format bispecific antibody triggering t-cell killing of b-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 2015; 5:17943; PMID:26659273; http://dx.doi.org/10.1038/srep17943 - DOI - PMC - PubMed